[A20-97] Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V

Last updated 20.05.2021

Project no.:
A20-97

Commission:
Commission awarded on 30.11.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy

Result of dossier assessment:

With Child-Pugh A or no liver cirrhosis: patients with viral aetiology of HCC: indication of major added benefit. Patients with non-viral aetiology of HCC: hint of considerable added benefit. With Child-Pugh B: added benefit not proven.

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Project no. Title Status
A19-86 Atezolizumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A19-84 Atezolizumab (NSCLC; combination with nab-paclitaxel and carboplatin) – Benefit assessment according to §35a Social Code Book V Commission completed
A19-83 Atezolizumab (NSCLC; combination with bevacizumab, carboplatin and paclitaxel) – Benefit assessment according to §35a Social Code Book V Commission completed
A19-81 Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A18-88 Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings) Commission completed
A17-51 Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V Commission completed
A17-52 Atezolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A17-50 Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V Commission completed
A21-45 Atezolizumab (hepatocellular carcinoma) - Addendum to Commission A20-97 Commission completed
A24-102 Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V Commission work started
A24-97 Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V Commission work started
A22-67 Atezolizumab (NSCLC) – Benefit assessment according to § 35a SGB V Commission completed
A21-69 Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V Commission completed

Federal Joint Committee (G-BA)

2021-05-20: A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form